Drugs / PF-06954522
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06393517 | Apr → Sep 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06279234 | Feb 2024 → Apr 2025 | obesity disorder, type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06003777 | Aug 2023 → Feb 2024 | — | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-06 | Nxera Pharma UK Limited | Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial nxera.life ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06954522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06003777 ↗ |
| Route | Oral | “PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.” NCT06003777 ↗ |